Qualigen Therapeutics, Inc. (NASDAQ:QLGN – Get Free Report) shares were up 1% during trading on Thursday . The company traded as high as $1.06 and last traded at $1.05. 10,264 shares were traded during mid-day trading, a decline of 99% from the average daily volume of 1,521,488 shares. The stock had previously closed at $1.04.
Qualigen Therapeutics Stock Performance
The company’s fifty day simple moving average is $1.28 and its two-hundred day simple moving average is $1.53. The stock has a market capitalization of $1.73 million, a P/E ratio of -0.14 and a beta of 0.24.
Qualigen Therapeutics Company Profile
Qualigen Therapeutics, Inc (NASDAQ: QLGN) is a life sciences company headquartered in Westminster, Colorado, that combines immunodiagnostic reagents with novel immuno-oncology therapies. Operating through two primary business units—Qualigen Diagnostic Solutions and Qualigen BioTherapeutics—the company seeks to leverage its expertise in antibody engineering and assay development to address both clinical laboratory needs and unmet medical needs in oncology.
Through its Qualigen Diagnostic Solutions division, the company designs, manufactures and distributes immunoassay reagents, kits and related consumables for use in clinical and research laboratories.
Further Reading
- Five stocks we like better than Qualigen Therapeutics
- Starbucks Builds Sovereign AI to Cut $400 Million in Software Costs
- Power Struggle: Wolfspeed Sues Navitas Over AI Chips
- Why WD-40 Is Proving Great Businesses Never Go Out of Style
- Pushing the Edge: Super Micro Computer Reboots the AI Landscape
Receive News & Ratings for Qualigen Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qualigen Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
